With 47.8 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.18 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $14.5 whereas the lowest price it dropped to was $7.11. The 52-week range on VERO shows that it touched its highest point at $17.49 and its lowest point at $2.16 during that stretch. It currently has a 1-year price target of $116.60. Beta for the stock currently stands at -0.13.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VERO was up-trending over the past week, with a rise of 295.13%, but this was up by 224.73% over a month. Three-month performance surged to 76.87% while six-month performance rose 77.87%. The stock gained 21.35% in the past year, while it has gained 115.62% so far this year. A look at the trailing 12-month EPS for VERO yields -77.30 with Next year EPS estimates of -27.53. For the next quarter, that number is -14.62. This implies an EPS growth rate of 29.42% for this year and 45.22% for next year.
Float and Shares Shorts:
On 2025-03-14, short shares totaled 33605.0, which was 509.99999999999994 higher than short shares on 1739491200. In addition to Mr. Rajiv Kanishka Liyanaarchchie De Silva as the firm’s CEO & Director, Mr. Ross J. Portaro serves as its EVP-Commercial Strategy, Head of Venus Hair, GM of Global Sales & Marketing.
Institutional Ownership:
Through their ownership of 0.29322 of VERO’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, VERO reported revenue of $15765000.0 and operating income of -$6671000.0. The EBITDA in the recently reported quarter was -$5706000.0 and diluted EPS was -$11.229999.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VERO since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$72.50433 being high and -$77.86677 being low. For VERO, this leads to a yearly average estimate of -$75.18555. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
